HB 2198
Alternative Names: HB-2198Latest Information Update: 14 Feb 2025
At a glance
- Originator Hinge Bio
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 23 Jan 2025 Hinge Bio has patent protection for platform compositions of matter and methods for their synthesis and use (Hinge Bio pipeline, January 2025)
- 16 Jan 2025 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)
- 16 Jan 2025 Pharmacodynamics data from a preclinical studies in Systemic lupus erythematosus released by Hinge Bio